Nuvectis Pharma Stock (NASDAQ:NVCT)
Previous Close
$6.41
52W Range
$5.85 - $12.10
50D Avg
$6.80
200D Avg
$7.16
Market Cap
$117.70M
Avg Vol (3M)
$118.31K
Beta
0.45
Div Yield
-
NVCT Company Profile
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT Performance
Peer Comparison
Ticker | Company |
---|---|
OLMA | Olema Pharmaceuticals, Inc. |
GOSS | Gossamer Bio, Inc. |
CGEM | Cullinan Oncology, Inc. |
DBTX | Decibel Therapeutics, Inc. |
IVA | Inventiva S.A. |
CNTA | Centessa Pharmaceuticals plc |
IKNA | Ikena Oncology, Inc. |
LRMR | Larimar Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
OBIO | Orchestra BioMed Holdings, Inc. |
REPL | Replimune Group, Inc. |
KRON | Kronos Bio, Inc. |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
NAMS | NewAmsterdam Pharma Company N.V. |
HOWL | Werewolf Therapeutics, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
LYRA | Lyra Therapeutics, Inc. |
CELC | Celcuity Inc. |
CMPX | Compass Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |